These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 1653205)

  • 1. The inhibition of supercoiling activity of DNA gyrase from Micrococcus luteus caused by rufloxacin (MF 934) and MF 961.
    Fabbri S; Broggini M; Pagella P; D'Incalci M
    J Antimicrob Chemother; 1991 May; 27(5):687-9. PubMed ID: 1653205
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanism of action of the des-F(6) quinolone BMS-284756 measured by supercoiling inhibition and cleavable complex assays.
    Wu P; Lawrence LE; Denbleyker KL; Barrett JF
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3660-2. PubMed ID: 11709365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereo (C7)-dependent topoisomerase II inhibition and tumor growth suppression by a new quinolone, BO-2367.
    Yoshinari T; Mano E; Arakawa H; Kurama M; Iguchi T; Nakagawa S; Tanaka N; Okura A
    Jpn J Cancer Res; 1993 Jul; 84(7):800-6. PubMed ID: 8396568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discrepancy between the antibacterial activities and the inhibitory effects on Micrococcus luteus DNA gyrase of 13 quinolones.
    Fu KP; Grace ME; McCloud SJ; Gregory FJ; Hung PP
    Chemotherapy; 1986; 32(6):494-8. PubMed ID: 3026740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clerocidin, a terpenoid antibiotic, inhibits bacterial DNA gyrase.
    McCullough JE; Muller MT; Howells AJ; Maxwell A; O'Sullivan J; Summerill RS; Parker WL; Wells JS; Bonner DP; Fernandes PB
    J Antibiot (Tokyo); 1993 Mar; 46(3):526-30. PubMed ID: 8386713
    [No Abstract]   [Full Text] [Related]  

  • 6. 4-quinolones and the physiology of DNA gyrase.
    Drlica K; Kreiswirth B
    Adv Pharmacol; 1994; 29A():263-83. PubMed ID: 7826862
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibition by quinolones of DNA gyrase from Staphylococcus aureus.
    Tanaka M; Sato K; Kimura Y; Hayakawa I; Osada Y; Nishino T
    Antimicrob Agents Chemother; 1991 Jul; 35(7):1489-91. PubMed ID: 1656864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic profile of a nalidixic acid analog: a model for the mechanism of sister chromatid exchange induction.
    Holden HE; Barett JF; Huntington CM; Muehlbauer PA; Wahrenburg MG
    Environ Mol Mutagen; 1989; 13(3):238-52. PubMed ID: 2539998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids.
    Zweerink MM; Edison A
    Antimicrob Agents Chemother; 1986 Apr; 29(4):598-601. PubMed ID: 3010848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inhibitory activity of NM394, the active form of prodrug prulifloxacin against type II topoisomerase from Pseudomonas aeruginosa].
    Tani M; Maebashi K; Araake M; Watabe H
    Jpn J Antibiot; 2002 Dec; 55(6):882-5. PubMed ID: 12621742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The in-vitro activity of two new quinolones: rufloxacin and MF 961.
    Wise R; Andrews JM; Matthews R; Wolstenholme M
    J Antimicrob Chemother; 1992 Jun; 29(6):649-60. PubMed ID: 1324239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rufloxacin (MF-934): in vitro and in vivo antibacterial activity.
    Ravizzola G; Pinsi G; Pirali F; Colombrita D; Foresti I; Peroni L; Turano A
    Drugs Exp Clin Res; 1989; 15(1):11-5. PubMed ID: 2743869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory activity on DNA gyrase and intracellular accumulation of quinolones: structure-activity relationship of Q-35 analogs.
    Ito T; Kojima K; Koizumi K; Nagano H; Nishino T
    Biol Pharm Bull; 1994 Jul; 17(7):927-30. PubMed ID: 8000379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.
    Takei M; Fukuda H; Kishii R; Hosaka M
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3544-7. PubMed ID: 11709337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
    Matrat S; Petrella S; Cambau E; Sougakoff W; Jarlier V; Aubry A
    Antimicrob Agents Chemother; 2007 May; 51(5):1643-8. PubMed ID: 17325221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro cleavable-complex assay to monitor antimicrobial potency of quinolones.
    Walton L; Elwell LP
    Antimicrob Agents Chemother; 1988 Jul; 32(7):1086-9. PubMed ID: 2847641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of quinolones on DNA gyrase of Escherichia coli and topoisomerase II of fetal calf thymus.
    Hoshino K; Sato K; Une T; Osada Y
    Antimicrob Agents Chemother; 1989 Oct; 33(10):1816-8. PubMed ID: 2556080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new tricyclic fluoroquinolone, rufloxacin (MF-934), with interesting antibacterial and pharmacokinetic characteristics.
    Segre G; Cerretani D; Cerri D; Moltoni L
    Drugs Exp Clin Res; 1988; 14(12):747-54. PubMed ID: 3253051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Micrococcus luteus DNA gyrase: active components and a model for its supercoiling of DNA.
    Liu LF; Wang JC
    Proc Natl Acad Sci U S A; 1978 May; 75(5):2098-102. PubMed ID: 276855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility of Salmonella typhi and Brucella melitensis to the new fluoroquinolone rufloxacin (MF 934).
    Qadri SM; Ayub A; Ueno Y; Saldin H
    Chemotherapy; 1993; 39(5):311-4. PubMed ID: 8396527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.